Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CNS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CNS and 80,000+ other tickers.
See exactly how CNS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNS and 80,000+ other tickers.
Cohen & Steers, Inc. operates as a publicly traded holding company specializing in asset management. Through its various operating units, the firm delivers financial services to institutional investors, such as pension funds, university endowments, and charitable foundations. Its subsidiaries are tasked with managing bespoke client portfolios across equities, fixed income, multi-asset strategies, and commodities. Additionally, these subsidiaries develop and oversee a diverse range of investment vehicles, including mutual funds (focused on equity, fixed income, balanced, and multi-asset…
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.
NEW YORK, July 20, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Erik Schneberger as Executive Vice President, Chief Marketing Officer. Based in New York, Mr.
Cohen & Steers, Inc. is now rated Hold after a strong rally closed the prior valuation gap. CNS's Q2 saw net inflows of $1.3B and AUM rise to $100.1B, signaling renewed interest in public real estate. Operating margin expanded to 36.3% on revenue growth, with scope to reach 37% in H2 if markets remain stable.
Cohen & Steers, Inc. (CNS) Q2 2026 Earnings Call Transcript
Cohen & Steers NYSE: CNS reported higher second-quarter 2026 adjusted earnings and assets under management, as executives pointed to improving demand for real estate, infrastructure, preferred securities and broader real assets strategies.